Downregulation of TMEM220-AS1 is associated with gastric cancer development

Long non-coding RNAs (lncRNAs) have emerged as crucial regulators in a wide array of biological mechanisms. Recent studies have demonstrated their strong association with both functional and pathological aspects of gastric cancer (GC) its progression. Nonetheless, the specific role of TMEM220-AS1 in gastric tumorigenesis remains poorly characterized. This study aimed to elucidate the functional involvement of TMEM220-AS1 in gastric cancer and assess its potential as a diagnostic and prognostic biomarker. The novelty of this work lies in its exclusive focus on TMEM220-AS1 within the context of gastric cancer, a setting not previously explored. TMEM220-AS1 was identified through integrated bioinformatic screening, followed by validation of its expression profile in gastric cancer specimens. The Cancer Genome Atlas (TCGA) genomic repository was used to analyze the expression levels of TMEM220-AS1. Furthermore, the findings were validated in a subset of clinical specimens using qRT-PCR. LncRNA TMEM220-AS1’s clinical relevance was analyzed using the TCGA-derived transcriptomic data and matched clinical profiles. The diagnostic utility of this lncRNA was further explored using ROC curve analysis. As a last step, the functional analysis of TMEM220-AS1 was evaluated by bioinformatics approaches. The current investigation indicates that gastric cancer samples exhibited significant downregulation of LncRNA TMEM220-AS1 expression compared to non-neoplastic gastric tissues, and these reduced levels were not associated with the clinical characteristics of the patients. Additionally, ROC curve analysis suggests that the expression pattern of LncRNA TMEM220-AS1 may serve as a promising diagnostic indicator for gastric cancer. Functional annotation via in silico tools revealed TMEM220-AS1’s involvement in diverse biological pathways, such as complement and coagulation cascades, peroxisomal activity, histidine metabolism, cholesterol homeostasis, and fatty acid breakdown. In conclusion, TMEM220-AS1 was significantly downregulated in gastric cancer tissues compared with adjacent non-cancerous tissues and public normal tissue datasets. ROC curve analysis indicated preliminary discriminatory potential for distinguishing gastric cancer tissues from non-cancerous tissues. However, because no independent diagnostic validation cohort, survival analysis, functional assay, animal model, or mechanistic validation was included, these findings should be considered exploratory. The current data do not establish TMEM220-AS1 as a clinically validated biomarker or confirmed regulator of gastric cancer progression. Larger independent cohorts and experimental studies are required to determine its diagnostic accuracy, clinicopathological relevance, prognostic value, and biological function.